Alnylam Pharmaceuticals seeks an imaginative physician drug developer able to work across diseases in the neurology and hematology therapeutic area. The role provides clinical leadership in developing RNAi therapeutics across a portfolio spanning rare genetic and common diseases. The primary assignment is to serve as one of the clinical study leads for the plasminogen program as it transitions from Phase 2 to Phase 3. Reporting to the program clinical development strategy lead, the Director will help shape overall clinical development strategy and drive progress and operational excellence for clinical trials. The role involves extensive consultation and collaboration with external experts and cross-functional work with Regulatory, Biostatistics, Clinical Operations, Preclinical, Commercial, and Quality Assurance teams. The Director will also represent Alnylam Development at external meetings, including regulatory interactions and scientific meetings. Alnylam is a leader in RNAi therapeutics, a field with the potential to transform treatment for rare and common diseases. The company describes its culture as grounded in fierce innovation, passion for excellence, purposeful urgency, openness, and commitment to people. Alnylam is committed to inclusive recruitment and equal employment opportunity. This is a full-time role eligible for annual short-term and long-term incentive awards. The U.S. base salary range is $255,000–$345,000, with pay determined by factors including relevant experience, skills, and education. Benefits include medical, dental, and vision coverage; life and disability insurance; a lifestyle reimbursement program; flexible spending and health savings accounts; a 401(k) with company match; paid time off, wellness days, holidays, company-wide recharge breaks, and family resources and leave.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree